Réponse au sécukinumab sur la synovite en utilisant l'échographie Doppler puissance dans le rhumatisme psoriasique : résultats à 12 semaines d'une étude de phase III, ULTIMATE
doi: 10.1093/rheumatology/keab628
D'Agostino, et al. aimed to evaluate whether treatment with secukinumab inhibits synovitis in patients with active PsA, as measured by PDUS. They found that secukinumab rapidly and significantly decreased synovitis, indicating a direct effect of IL-17 inhibition on the synovium in patients with PsA.